<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
         xmlns="http://purl.org/rss/1.0/"
         xmlns:admin="http://webns.net/mvcb/"
         xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
         xmlns:dc="http://purl.org/dc/elements/1.1/"
         xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
  <channel rdf:about="https://hstalks.com/rss/?biosci">
    <title>The Biomedical &amp; Life Sciences Collection</title>
    <link>https://hstalks.com/biosci/</link>
    <description>New and updated series &amp; talks from HSTalks&#x27; Biomedical &amp; Life Sciences Collection.</description>
    <admin:generatorAgent rdf:resource="http://www.hstalks.com/" />
    <admin:errorReportsTo rdf:resource="mailto:info@hstalks.com" />
    <sy:updatePeriod>daily</sy:updatePeriod>
    <sy:updateFrequency>1</sy:updateFrequency>
    <sy:updateBase>2006-01-01T12:00+00:00</sy:updateBase>
    <dc:publisher>Henry Stewart Talks</dc:publisher>
    <dc:language>en</dc:language>
    <dc:rights>© Copyright Henry Stewart Talks Ltd.</dc:rights>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
    <prism:copyright>© Copyright Henry Stewart Talks Ltd.</prism:copyright>
    <items>
      <rdf:Seq>
      <rdf:li resource="https://hstalks.com/t/3391/palin-parent-child-interaction-therapy/?biosci" />
      <rdf:li resource="https://hstalks.com/t/3602/bridging-our-mandates-evidence-based-practice-ebp-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/3603/bridging-our-mandates-evidence-based-practice-ebp-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/3404/teenagers-and-stuttering-management-are-they-ready/?biosci" />
      <rdf:li resource="https://hstalks.com/t/3588/treatment-of-stuttering-during-the-pre-school-year/?biosci" />
      <rdf:li resource="https://hstalks.com/playlist/2205/developing-gene-therapies/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27458/precision-medicine/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27418/p-values-in-clinical-research/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27448/confidence-intervals/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27416/biostatistics-in-clinical-trials/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27382/in-vitro-vs-in-vivo-vs-in-silico-models/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22796/parasitic-diseases-causes-mechanisms-and-clinical-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/24413/the-human-microbiome-in-health-disease/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27383/high-throughput-screening/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27457/biomarkers-in-drug-development/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27449/real-world-evidence/?biosci" />
      <rdf:li resource="https://hstalks.com/t/24084/the-environment-scleroderma/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22828/vitamin-d/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23785/microbes-and-disease/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23026/gene-therapies-economics-access-barriers-commercia/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27415/protein-purification/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23752/the-olfactory-system/?biosci" />
      <rdf:li resource="https://hstalks.com/t/24314/natural-ligands-of-nuclear-receptors/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22829/pathophysiology-of-type-1-and-type-2-diabetes/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23851/long-term-follow-up-of-gene-therapy-trial-particip/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27450/formulation-development/?biosci" />
      <rdf:li resource="https://hstalks.com/t/26095/immunological-biomarkers-in-cabozantinib-and-nivol/?biosci" />
      <rdf:li resource="https://hstalks.com/t/24280/peroxisome-proliferator-activated-receptors-ppar-n/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23488/evolutionary-perspectives-on-human-microbiota-a-jo/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22795/bioavailability-of-micronutrients-minerals-and-vit/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23455/new-standards-in-weight-management/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22762/regulatory-considerations-in-the-development-of-ge/?biosci" />
      <rdf:li resource="https://hstalks.com/playlist/1446/key-concepts-how-to-learn/?biosci" />
      
      </rdf:Seq>
    </items>
  </channel>

  <item rdf:about="https://hstalks.com/t/3391/palin-parent-child-interaction-therapy/?biosci">
    <title>Palin parent-child interaction therapy [33 mins] </title>
    <link>https://hstalks.com/t/3391/palin-parent-child-interaction-therapy/?biosci</link>
    <description>Multifactorial model of onset &amp; development of stuttering - Therapeutic approach: core values - Risk factors for young children who stutter - Screening for vulnerability to persistence and appropriate care pathways - Assessment of stuttering - Principles of Palin parent-child interaction (PCI) therapy - Using video analysis in PCI therapy - Three main strands of PCI therapy: interaction, family, child (strategies)</description>
    <dc:title>Palin parent-child interaction therapy</dc:title>
    
    <dc:creator>Ms. Elaine Kelman</dc:creator>
    
    <dc:subject>Multifactorial model of onset &amp; development of stuttering, Therapeutic approach: core values, Risk factors for young children who stutter, Screening for vulnerability to persistence and appropriate care pathways, Assessment of stuttering, Principles of Palin parent-child interaction (PCI) therapy, Using video analysis in PCI therapy, Three main strands of PCI therapy: interaction, family, child (strategies)</dc:subject>
    <dc:date>2026-11-03</dc:date>
    <prism:publicationDate>2026-11-03</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/3602/bridging-our-mandates-evidence-based-practice-ebp-/?biosci">
    <title>Bridging our mandates: evidence-based practice (EBP) and patient-centered care (PCC) 1 [33 mins] </title>
    <link>https://hstalks.com/t/3602/bridging-our-mandates-evidence-based-practice-ebp-/?biosci</link>
    <description>Principles of evidence-based practice (EBP) - The process model - Linear vs. continuous EBP - Changing therapy approaches - Treatment of early stuttering - The acceptable time to wait for therapy progress - Patient-centered care (PCC) - Seeking a single best therapy for any condition - Important questions that need asking</description>
    <dc:title>Bridging our mandates: evidence-based practice (EBP) and patient-centered care (PCC) 1</dc:title>
    
    <dc:creator>Prof. Nan Bernstein Ratner</dc:creator>
    
    <dc:subject>Principles of evidence-based practice (EBP), The process model, Linear vs. continuous EBP, Changing therapy approaches, Treatment of early stuttering, The acceptable time to wait for therapy progress, Patient-centered care (PCC), Seeking a single best therapy for any condition, Important questions that need asking</dc:subject>
    <dc:date>2026-11-02</dc:date>
    <prism:publicationDate>2026-11-02</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/3603/bridging-our-mandates-evidence-based-practice-ebp-/?biosci">
    <title>Bridging our mandates: evidence-based practice (EBP) and patient-centered care (PCC) 2 [31 mins] </title>
    <link>https://hstalks.com/t/3603/bridging-our-mandates-evidence-based-practice-ebp-/?biosci</link>
    <description>Practice-based evidence (PBE) - &#x27;Evidence-farming&#x27; (harnessing PBE) - Benefits of evidence farming - Outcome due to &quot;good&quot; therapy approaches - Common factors in therapy - Clinician matters as much as the therapy - Factors that tend to enhance patient-centered care - The precarious place of clinical educators</description>
    <dc:title>Bridging our mandates: evidence-based practice (EBP) and patient-centered care (PCC) 2</dc:title>
    
    <dc:creator>Prof. Nan Bernstein Ratner</dc:creator>
    
    <dc:subject>Practice-based evidence (PBE), &#x27;Evidence-farming&#x27; (harnessing PBE), Benefits of evidence farming, Outcome due to &quot;good&quot; therapy approaches, Common factors in therapy, Clinician matters as much as the therapy, Factors that tend to enhance patient-centered care, The precarious place of clinical educators</dc:subject>
    <dc:date>2026-11-02</dc:date>
    <prism:publicationDate>2026-11-02</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/3404/teenagers-and-stuttering-management-are-they-ready/?biosci">
    <title>Teenagers and stuttering management: are they ready? [55 mins] </title>
    <link>https://hstalks.com/t/3404/teenagers-and-stuttering-management-are-they-ready/?biosci</link>
    <description>Motivation - Readiness can change - Motivational interviewing - The stages of change model - Decisional balance - Self-efficacy - Staging algorithm: stuttering management - UISPEAKS program for teens - Therapy map</description>
    <dc:title>Teenagers and stuttering management: are they ready?</dc:title>
    
    <dc:creator>Prof. Patricia Zebrowski</dc:creator>
    
    <dc:subject>Motivation, Readiness can change, Motivational interviewing, The stages of change model, Decisional balance, Self-efficacy, Staging algorithm: stuttering management, UISPEAKS program for teens, Therapy map</dc:subject>
    <dc:date>2026-11-02</dc:date>
    <prism:publicationDate>2026-11-02</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/3588/treatment-of-stuttering-during-the-pre-school-year/?biosci">
    <title>Treatment of stuttering during the pre-school years [19 mins] </title>
    <link>https://hstalks.com/t/3588/treatment-of-stuttering-during-the-pre-school-year/?biosci</link>
    <description>Treatment of stuttering during the preschool years - Why treat early stuttering? - Two different types of treatment - Clinical trials - Advantages and disadvantages of two types of treatment - The future for the field</description>
    <dc:title>Treatment of stuttering during the pre-school years</dc:title>
    
    <dc:creator>Prof. Mark Onslow</dc:creator>
    
    <dc:subject>Treatment of stuttering during the preschool years, Why treat early stuttering?, Two different types of treatment, Clinical trials, Advantages and disadvantages of two types of treatment, The future for the field</dc:subject>
    <dc:date>2026-11-01</dc:date>
    <prism:publicationDate>2026-11-01</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/playlist/2205/developing-gene-therapies/?biosci">
    <title>Developing Gene Therapies [series]</title>
    <link>https://hstalks.com/playlist/2205/developing-gene-therapies/?biosci</link>
    <description>Core principles of gene therapy (GTx) product development - Unmet medical needs addressed by GTx - Emerging business models, industry standards and best practices for GTx - Statistical design and analysis aspects of clinical trials of GTx - Case studies of successful development of GTx - Emerging global regulatory pathways for GTx - Benefits of GTx in the coming years from a multi-stakeholder perspective</description>
    <dc:title>Developing Gene Therapies</dc:title>
    <dc:creator>Dr. Avery McIntosh</dc:creator>
    <dc:creator>Dr. Alex Sverdlov</dc:creator>
    
    
    <dc:subject>Core principles of gene therapy (GTx) product development, Unmet medical needs addressed by GTx, Emerging business models, industry standards and best practices for GTx, Statistical design and analysis aspects of clinical trials of GTx, Case studies of successful development of GTx, Emerging global regulatory pathways for GTx, Benefits of GTx in the coming years from a multi-stakeholder perspective</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27458/precision-medicine/?biosci">
    <title>Precision medicine [4 mins] </title>
    <link>https://hstalks.com/t/27458/precision-medicine/?biosci</link>
    <description>Precision Medicine Foundations - Genomic &amp; Molecular Profiling - Biomarkers &amp; Pharmacogenomics - Applications in Oncology &amp; Cardiology - Variant Interpretation Challenges - AI &amp; Multi-Omics Integration</description>
    <dc:title>Precision medicine</dc:title>
    
    
    <dc:subject>Precision Medicine Foundations, Genomic &amp; Molecular Profiling, Biomarkers &amp; Pharmacogenomics, Applications in Oncology &amp; Cardiology, Variant Interpretation Challenges, AI &amp; Multi-Omics Integration</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27418/p-values-in-clinical-research/?biosci">
    <title>P values in clinical research [4 mins] </title>
    <link>https://hstalks.com/t/27418/p-values-in-clinical-research/?biosci</link>
    <description>Basics of p values - Interpreting p values - Misconceptions about p values - Statistical vs clinical significance - Limitations of p values - P values in regulatory decisions - Study design, effect size, and context</description>
    <dc:title>P values in clinical research</dc:title>
    
    
    <dc:subject>Basics of p values, Interpreting p values, Misconceptions about p values, Statistical vs clinical significance, Limitations of p values, P values in regulatory decisions, Study design, effect size, and context</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27448/confidence-intervals/?biosci">
    <title>Confidence intervals [4 mins] </title>
    <link>https://hstalks.com/t/27448/confidence-intervals/?biosci</link>
    <description>Confidence interval definition - Importance of confidence intervals - Confidence intervals vs p-values - Confidence intervals in clinical decisions - Best practices for statistical analysis</description>
    <dc:title>Confidence intervals</dc:title>
    
    
    <dc:subject>Confidence interval definition, Importance of confidence intervals, Confidence intervals vs p-values, Confidence intervals in clinical decisions, Best practices for statistical analysis</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27416/biostatistics-in-clinical-trials/?biosci">
    <title>Biostatistics in clinical trials [5 mins] </title>
    <link>https://hstalks.com/t/27416/biostatistics-in-clinical-trials/?biosci</link>
    <description>Foundational role of biostatistics - Study design and randomisation - Hypothesis testing and significance - Addressing bias and reliability - Regulatory decisions and approval</description>
    <dc:title>Biostatistics in clinical trials</dc:title>
    
    
    <dc:subject>Foundational role of biostatistics, Study design and randomisation, Hypothesis testing and significance, Addressing bias and reliability, Regulatory decisions and approval</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27382/in-vitro-vs-in-vivo-vs-in-silico-models/?biosci">
    <title>In vitro vs in vivo vs in silico models [5 mins] </title>
    <link>https://hstalks.com/t/27382/in-vitro-vs-in-vivo-vs-in-silico-models/?biosci</link>
    <description>In vitro, in vivo, in silico models - Applications of model types - Strengths and limitations of each model - Challenges in translating preclinical findings - Integrating multiple models in research - Criteria for selecting research models</description>
    <dc:title>In vitro vs in vivo vs in silico models</dc:title>
    
    
    <dc:subject>In vitro, in vivo, in silico models, Applications of model types, Strengths and limitations of each model, Challenges in translating preclinical findings, Integrating multiple models in research, Criteria for selecting research models</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22796/parasitic-diseases-causes-mechanisms-and-clinical-/?biosci">
    <title>Parasitic diseases: causes, mechanisms, and clinical examples [26 mins] </title>
    <link>https://hstalks.com/t/22796/parasitic-diseases-causes-mechanisms-and-clinical-/?biosci</link>
    <description>Parasitic diseases - Types of parasites - Parasite’s inherent characteristics - Parasitic mechanisms of cell and tissue damage - Clinical examples of parasitic diseases - Diagnostic methods - Treatment - Prevention</description>
    <dc:title>Parasitic diseases: causes, mechanisms, and clinical examples</dc:title>
    
    <dc:creator>Prof. Hany Elsheikha</dc:creator>
    
    <dc:subject>Parasitic diseases, Types of parasites, Parasite’s inherent characteristics, Parasitic mechanisms of cell and tissue damage, Clinical examples of parasitic diseases, Diagnostic methods, Treatment, Prevention</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/24413/the-human-microbiome-in-health-disease/?biosci">
    <title>The human microbiome in health &amp; disease [46 mins] </title>
    <link>https://hstalks.com/t/24413/the-human-microbiome-in-health-disease/?biosci</link>
    <description>What is microbiome? - How we identify the composition of the microbiome? - Evidence for how the microbiome affect our bodies - Faecal Microbiota Transplantation (FMT) - Gut microbiota and obesity - Autism spectrum disorder and gut microbiome - Microbiome acquired during birth - Dysbiosis and ageing</description>
    <dc:title>The human microbiome in health &amp; disease</dc:title>
    
    <dc:creator>Dr. Martin Goldberg</dc:creator>
    
    <dc:subject>What is microbiome?, How we identify the composition of the microbiome?, Evidence for how the microbiome affect our bodies, Faecal Microbiota Transplantation (FMT), Gut microbiota and obesity, Autism spectrum disorder and gut microbiome, Microbiome acquired during birth, Dysbiosis and ageing</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27383/high-throughput-screening/?biosci">
    <title>High-throughput screening [4 mins] </title>
    <link>https://hstalks.com/t/27383/high-throughput-screening/?biosci</link>
    <description>HTS principles and workflow - Automation in screening - Assay development and validation - Data analysis and hit ID - Managing false results - Limitations and challenges of HTS - Technological advances in HTS</description>
    <dc:title>High-throughput screening</dc:title>
    
    
    <dc:subject>HTS principles and workflow, Automation in screening, Assay development and validation, Data analysis and hit ID, Managing false results, Limitations and challenges of HTS, Technological advances in HTS</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27457/biomarkers-in-drug-development/?biosci">
    <title>Biomarkers in drug development [4 mins] </title>
    <link>https://hstalks.com/t/27457/biomarkers-in-drug-development/?biosci</link>
    <description>Biomarker definition and importance - Types of biomarkers - Biomarkers in clinical decision-making - Clinical and drug development biomarkers - Analytical methods for biomarkers - Quality control in biomarker analysis - Advances in biomarker technology - Biomarkers in precision medicine</description>
    <dc:title>Biomarkers in drug development</dc:title>
    
    
    <dc:subject>Biomarker definition and importance, Types of biomarkers, Biomarkers in clinical decision-making, Clinical and drug development biomarkers, Analytical methods for biomarkers, Quality control in biomarker analysis, Advances in biomarker technology, Biomarkers in precision medicine</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27449/real-world-evidence/?biosci">
    <title>Real-world evidence [4 mins] </title>
    <link>https://hstalks.com/t/27449/real-world-evidence/?biosci</link>
    <description>Definition of real-world evidence - Primary data sources for RWE - RWE vs traditional clinical evidence - Importance of RWE in research and regulation - Opportunities and limitations of RWE - Regulatory agency role in RWE adoption - Examples of RWE impact</description>
    <dc:title>Real-world evidence</dc:title>
    
    
    <dc:subject>Definition of real-world evidence, Primary data sources for RWE, RWE vs traditional clinical evidence, Importance of RWE in research and regulation, Opportunities and limitations of RWE, Regulatory agency role in RWE adoption, Examples of RWE impact</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/24084/the-environment-scleroderma/?biosci">
    <title>The environment &amp; scleroderma [12 mins] </title>
    <link>https://hstalks.com/t/24084/the-environment-scleroderma/?biosci</link>
    <description>Systemic sclerosis (scleroderma) - Pathogenesis of systemic sclerosis (SSc) - Gene-susceptibility and gene-environment interaction in SSc - Environmental risk factors - Epigenetic impact of toxins - Infectious triggers - Microbiome alteration in SSc - Medications associated with scleroderma-like skin changes or scleroderma</description>
    <dc:title>The environment &amp; scleroderma</dc:title>
    
    <dc:creator>Dr. Zsuzsanna McMahan</dc:creator>
    
    <dc:subject>Systemic sclerosis (scleroderma), Pathogenesis of systemic sclerosis (SSc), Gene-susceptibility and gene-environment interaction in SSc, Environmental risk factors, Epigenetic impact of toxins, Infectious triggers, Microbiome alteration in SSc, Medications associated with scleroderma-like skin changes or scleroderma</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22828/vitamin-d/?biosci">
    <title>Vitamin D [8 mins] </title>
    <link>https://hstalks.com/t/22828/vitamin-d/?biosci</link>
    <description>Functions in the body - Food sources - Absorption - Metabolism - Biomarkers of intake &amp; status - Deficiency - Excess intake - Dietary reference values of Vitamin D for adults - Further resources</description>
    <dc:title>Vitamin D</dc:title>
    
    <dc:creator>Prof. Susan Fairweather-Tait</dc:creator>
    
    <dc:subject>Functions in the body, Food sources, Absorption, Metabolism, Biomarkers of intake &amp; status, Deficiency, Excess intake, Dietary reference values of Vitamin D for adults, Further resources</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23785/microbes-and-disease/?biosci">
    <title>Microbes and disease [50 mins] </title>
    <link>https://hstalks.com/t/23785/microbes-and-disease/?biosci</link>
    <description>Entry &amp; colonisation of body by pathogens - Quorum sensing - Spread of pathogens within host - Pathophysiology of microbial diseases - Endotoxins and exotoxins - Escape and spread to new hosts - Opportunists vs. obligate pathogens</description>
    <dc:title>Microbes and disease</dc:title>
    
    <dc:creator>Dr. Martin Goldberg</dc:creator>
    
    <dc:subject>Entry &amp; colonisation of body by pathogens, Quorum sensing, Spread of pathogens within host, Pathophysiology of microbial diseases, Endotoxins and exotoxins, Escape and spread to new hosts, Opportunists vs. obligate pathogens</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23026/gene-therapies-economics-access-barriers-commercia/?biosci">
    <title>Gene therapies: economics, access barriers &amp; commercial models [41 mins] </title>
    <link>https://hstalks.com/t/23026/gene-therapies-economics-access-barriers-commercia/?biosci</link>
    <description>Gene therapy - Rare diseases - Economic challenges of gene therapies - Patient access - Real world evidences - Health technology assessment - Patient advocacy groups - Clinical development plan - Market development plant</description>
    <dc:title>Gene therapies: economics, access barriers &amp; commercial models</dc:title>
    
    <dc:creator>Dr. Kasem S. Akhras</dc:creator>
    
    <dc:subject>Gene therapy, Rare diseases, Economic challenges of gene therapies, Patient access, Real world evidences, Health technology assessment, Patient advocacy groups, Clinical development plan, Market development plant</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci">
    <title>Targeting the intestinal barrier in GVHD and checkpoint colitis [20 mins] </title>
    <link>https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci</link>
    <description>Acute graft-versus-host disease (aGVHD): Clinical presentation - Intestinal inflammation during aGVHD - Treatment of aGVHD - Kinase targets in GVHD - REACH2 trial - Colitis and other irAEs after immune checkpoint blockade - ECP is an effective therapy for inflammatory diseases - Arginase-1 is central in ECP-induced immunomodulation</description>
    <dc:title>Targeting the intestinal barrier in GVHD and checkpoint colitis</dc:title>
    
    <dc:creator>Prof. Robert Zeiser</dc:creator>
    
    <dc:subject>Acute graft-versus-host disease (aGVHD): Clinical presentation, Intestinal inflammation during aGVHD, Treatment of aGVHD, Kinase targets in GVHD, REACH2 trial, Colitis and other irAEs after immune checkpoint blockade, ECP is an effective therapy for inflammatory diseases, Arginase-1 is central in ECP-induced immunomodulation</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27415/protein-purification/?biosci">
    <title>Protein purification [4 mins] </title>
    <link>https://hstalks.com/t/27415/protein-purification/?biosci</link>
    <description>Protein purification basics - Recombinant expression systems - Protein recovery steps - Purification chromatography methods - Analytical yield and purity methods - Scale-up challenges and strategies</description>
    <dc:title>Protein purification</dc:title>
    
    
    <dc:subject>Protein purification basics, Recombinant expression systems, Protein recovery steps, Purification chromatography methods, Analytical yield and purity methods, Scale-up challenges and strategies</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23752/the-olfactory-system/?biosci">
    <title>The olfactory system [35 mins] </title>
    <link>https://hstalks.com/t/23752/the-olfactory-system/?biosci</link>
    <description>Role of olfaction in smell, food flavor, and appetite - Impact of losing your sense of smell - Odor and odorants - Olfactory sensory neurons, receptors, and signal transduction - Olfactory receptors are mapped onto the olfactory bulb - Spatiotemporal pattern of glomerular activity encodes odor features - Primary olfactory cortex - Piriform cortex</description>
    <dc:title>The olfactory system</dc:title>
    
    <dc:creator>Prof. Adam Dewan</dc:creator>
    
    <dc:subject>Role of olfaction in smell, food flavor, and appetite, Impact of losing your sense of smell, Odor and odorants, Olfactory sensory neurons, receptors, and signal transduction, Olfactory receptors are mapped onto the olfactory bulb, Spatiotemporal pattern of glomerular activity encodes odor features, Primary olfactory cortex, Piriform cortex</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/24314/natural-ligands-of-nuclear-receptors/?biosci">
    <title>Natural ligands of nuclear receptors [10 mins] </title>
    <link>https://hstalks.com/t/24314/natural-ligands-of-nuclear-receptors/?biosci</link>
    <description>Natural nuclear receptor ligands - Vitamins and steroids as nuclear receptor ligands - Nuclear receptors and nuclear receptors ligands - Negative feedback mechanisms - Lipid and metabolite sensing nuclear receptors - Xenobiotic sensors</description>
    <dc:title>Natural ligands of nuclear receptors</dc:title>
    
    <dc:creator>Prof. Dr. Daniel Merk</dc:creator>
    
    <dc:subject>Natural nuclear receptor ligands, Vitamins and steroids as nuclear receptor ligands, Nuclear receptors and nuclear receptors ligands, Negative feedback mechanisms, Lipid and metabolite sensing nuclear receptors, Xenobiotic sensors</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22829/pathophysiology-of-type-1-and-type-2-diabetes/?biosci">
    <title>Pathophysiology of type 1 and type 2 diabetes [18 mins] </title>
    <link>https://hstalks.com/t/22829/pathophysiology-of-type-1-and-type-2-diabetes/?biosci</link>
    <description>Diabetes - Insulin - Type 1 diabetes - Diabetic ketoacidosis - Type 2 diabetes - Hyperosmolar nonketotic coma - Impaired fasting glucose - Key differences between type 1 and type 2 diabetes</description>
    <dc:title>Pathophysiology of type 1 and type 2 diabetes</dc:title>
    
    <dc:creator>Prof. Karim Meeran</dc:creator>
    
    <dc:subject>Diabetes, Insulin, Type 1 diabetes, Diabetic ketoacidosis, Type 2 diabetes, Hyperosmolar nonketotic coma, Impaired fasting glucose, Key differences between type 1 and type 2 diabetes</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23851/long-term-follow-up-of-gene-therapy-trial-particip/?biosci">
    <title>Long-term follow-up of gene therapy trial participants: practical and statistical considerations [22 mins] </title>
    <link>https://hstalks.com/t/23851/long-term-follow-up-of-gene-therapy-trial-particip/?biosci</link>
    <description>Long-term follow-up of gene therapy (LTFU) - History of LTFU - Gene therapy registries - Platform trials - Bespoke Gene Therapy Consortium (BGTC) - Mock schedule of assessments - Bayesian hierarchical modelling - EXNEX</description>
    <dc:title>Long-term follow-up of gene therapy trial participants: practical and statistical considerations</dc:title>
    
    <dc:creator>Dr. Avery McIntosh</dc:creator>
    
    <dc:subject>Long-term follow-up of gene therapy (LTFU), History of LTFU, Gene therapy registries, Platform trials, Bespoke Gene Therapy Consortium (BGTC), Mock schedule of assessments, Bayesian hierarchical modelling, EXNEX</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27450/formulation-development/?biosci">
    <title>Formulation development [4 mins] </title>
    <link>https://hstalks.com/t/27450/formulation-development/?biosci</link>
    <description>Formulation development stages - Drug stability &amp; bioavailability - Excipients &amp; delivery systems - Solubility enhancement &amp; taste masking - Regulatory &amp; quality assurance - Stability &amp; bioequivalence testing - Quality by Design &amp; risk management</description>
    <dc:title>Formulation development</dc:title>
    
    
    <dc:subject>Formulation development stages, Drug stability &amp; bioavailability, Excipients &amp; delivery systems, Solubility enhancement &amp; taste masking, Regulatory &amp; quality assurance, Stability &amp; bioequivalence testing, Quality by Design &amp; risk management</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/26095/immunological-biomarkers-in-cabozantinib-and-nivol/?biosci">
    <title>Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer [19 mins] </title>
    <link>https://hstalks.com/t/26095/immunological-biomarkers-in-cabozantinib-and-nivol/?biosci</link>
    <description>Endometrial cancer immunotherapy - Immune biomarkers - Nivolumab - Cabozantinib - Tumour microenvironment - Macrophages - Personalised cancer treatment - Immunotherapy resistance</description>
    <dc:title>Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer</dc:title>
    
    <dc:creator>Prof. Sacha Gnjatic</dc:creator>
    
    <dc:subject>Endometrial cancer immunotherapy, Immune biomarkers, Nivolumab, Cabozantinib, Tumour microenvironment, Macrophages, Personalised cancer treatment, Immunotherapy resistance</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/24280/peroxisome-proliferator-activated-receptors-ppar-n/?biosci">
    <title>Peroxisome proliferator-activated receptors: PPARγ (NR1C3) – biological role and drugs [7 mins] </title>
    <link>https://hstalks.com/t/24280/peroxisome-proliferator-activated-receptors-ppar-n/?biosci</link>
    <description>Functions of PPARγ - Role of PPARγ in adipocytes and glucose homeostasis - Role of PPARγ in macrophage functions - PPARγ targeting drugs - PPARγ in MAFLD</description>
    <dc:title>Peroxisome proliferator-activated receptors: PPARγ (NR1C3) – biological role and drugs</dc:title>
    
    <dc:creator>Prof. Dr. Daniel Merk</dc:creator>
    
    <dc:subject>Functions of PPARγ, Role of PPARγ in adipocytes and glucose homeostasis, Role of PPARγ in macrophage functions, PPARγ targeting drugs, PPARγ in MAFLD</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23488/evolutionary-perspectives-on-human-microbiota-a-jo/?biosci">
    <title>Evolutionary perspectives on human microbiota: a journey through zoological and bacteriological realms [28 mins] </title>
    <link>https://hstalks.com/t/23488/evolutionary-perspectives-on-human-microbiota-a-jo/?biosci</link>
    <description>Microbiota description - Current view about microbiota - Bacterial genetics and evolution - Microbiota stability - Selective forces in microbiota - Selective forces in animal hosts</description>
    <dc:title>Evolutionary perspectives on human microbiota: a journey through zoological and bacteriological realms</dc:title>
    
    <dc:creator>Prof. Gabriel Trueba</dc:creator>
    
    <dc:subject>Microbiota description, Current view about microbiota, Bacterial genetics and evolution, Microbiota stability, Selective forces in microbiota, Selective forces in animal hosts</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22795/bioavailability-of-micronutrients-minerals-and-vit/?biosci">
    <title>Bioavailability of micronutrients (minerals and vitamins) [12 mins] </title>
    <link>https://hstalks.com/t/22795/bioavailability-of-micronutrients-minerals-and-vit/?biosci</link>
    <description>Bioavailability definition - Bioavailability pathway - Factors affecting bioavailability - Relative bioavailability - Assessment of bioavailability - Low or variable micronutrient bioavailability</description>
    <dc:title>Bioavailability of micronutrients (minerals and vitamins)</dc:title>
    
    <dc:creator>Prof. Susan Fairweather-Tait</dc:creator>
    
    <dc:subject>Bioavailability definition, Bioavailability pathway, Factors affecting bioavailability, Relative bioavailability, Assessment of bioavailability, Low or variable micronutrient bioavailability</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23455/new-standards-in-weight-management/?biosci">
    <title>New standards in weight management [41 mins] </title>
    <link>https://hstalks.com/t/23455/new-standards-in-weight-management/?biosci</link>
    <description>Trends in obesity - Strategies for obesity prevention - Interventions for treatment of obesity - Approved drugs for obesity treatment - Obesity management - Clinical trials</description>
    <dc:title>New standards in weight management</dc:title>
    
    <dc:creator>Prof. John Wilding</dc:creator>
    
    <dc:subject>Trends in obesity, Strategies for obesity prevention, Interventions for treatment of obesity, Approved drugs for obesity treatment, Obesity management, Clinical trials</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22762/regulatory-considerations-in-the-development-of-ge/?biosci">
    <title>Regulatory considerations in the development of gene therapy products [22 mins] </title>
    <link>https://hstalks.com/t/22762/regulatory-considerations-in-the-development-of-ge/?biosci</link>
    <description>Introduction to regulatory considerations in the development of gene therapy products - Regulatory definitions of gene therapy - Designations and expedited pathways - Unique regulatory considerations for gene therapy - Emerging regulatory trends</description>
    <dc:title>Regulatory considerations in the development of gene therapy products</dc:title>
    
    <dc:creator>Dr. Seoan Huh</dc:creator>
    
    <dc:subject>Introduction to regulatory considerations in the development of gene therapy products, Regulatory definitions of gene therapy, Designations and expedited pathways, Unique regulatory considerations for gene therapy, Emerging regulatory trends</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/playlist/1446/key-concepts-how-to-learn/?biosci">
    <title>Key Concepts: How to Learn [series]</title>
    <link>https://hstalks.com/playlist/1446/key-concepts-how-to-learn/?biosci</link>
    <description>Individual learning strategies - Note-taking - Generative AI and learning - Effective questioning - Critical thinking - Self-testing - Transfer of knowledge - Knowledge application - Interleaving - Learning</description>
    <dc:title>Key Concepts: How to Learn</dc:title>
    <dc:creator>Dr. Cynthia Nebel</dc:creator>
    
    
    <dc:subject>Individual learning strategies, Note-taking, Generative AI and learning, Effective questioning, Critical thinking, Self-testing, Transfer of knowledge, Knowledge application, Interleaving, Learning</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

</rdf:RDF>
